Last reviewed · How we verify
Modified-release morphine
At a glance
| Generic name | Modified-release morphine |
|---|---|
| Also known as | Modified-release morphine sulfate |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Postoperative Pain in Primary Cemented Total Knee Arthroplasty With or Without Drain (NA)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- Evaluation of the Effectiveness of Non-pharmacological Methods During Heel Blood Collection (NA)
- Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients (PHASE4)
- Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries? (NA)
- EMR Defaults to Nudge Opioid Prescribing (NA)
- Music Therapy to Restore Motor Deficits After Stroke (NA)
- Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Modified-release morphine CI brief — competitive landscape report
- Modified-release morphine updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI